Row No	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	13/WM/023	126333	ATrial FibrillaTion ProgrESsion Trial	Number Agreed	1	1	Date Agreed	01/08/2017	0	27/02/2018	5	Withdrawn By Sponsor
2	13/LO/0867	126972	Double-blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monother	Number Agreed	4	4	Date Agreed	30/03/2018	15	05/01/2018	15	Recruitment Finished
3	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable PleuralMesothelioma	Range Agreed	4	6	Date Agreed	30/06/2018	3	22/02/2018	3	Recruitment Finished
4	14/NI/1038	153733	A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL? used for Suture-Line Sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures	Range Agreed	1	6	Date Agreed	01/05/2019	2	05/01/2018	2	Recruitment Finished
5	15/NW/0827	181796	A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients withRelapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation	Number Agreed	4	4	Date Agreed	28/02/2017	0	20/02/2018	0	Recruitment Finished
6	17/NW/0145	217442	Longitudinal study of chronic wounds using novel wound measurement technologies	Range Agreed	10	15	Date Agreed	01/05/2018	16	31/01/2018	16	Recruitment Finished
7	17/EM/0044	217658	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).	Number Agreed	2	2	Date Agreed	31/05/2018	0	21/02/2018	0	Recruitment Finished
8	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	50	50	Date Agreed	03/09/2018	116	03/05/2018	116	Recruitment Finished
9	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	2	29/06/2018	2	Recruitment Finished
10	18/YH/0167	246108	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibr	Number Agreed	1	1	Date Agreed	31/12/2050	0	28/06/2018	0	Withdrawn By Sponsor

11	16/LO/0803	204170	Study of MiniMed? 640G Insulin Pump with SmartGuard? in prevention of Low Glucose Events in adults with Type 1diabetes	Range Agreed	5	7	Date Agreed	30/09/2017	6	03/04/2018	6	Recruitment Finished
12	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent patients with atypical hemolytic uremic syndrome (aHUS)	Range Agreed	1	1	Date Agreed	28/02/2018	0	01/06/2018	0	Recruitment Finished
13	17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF)	Number Agreed	12	12	Date Agreed	30/03/2018	9	06/04/2018	9	Recruitment Finished
14	16/WM/0511	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or withou	Range Agreed	3	4	Date Agreed	31/10/2017	2	15/03/2018	4	Recruitment Finished
15	17/LO/1502	232726	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS443139 in Huntington?s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139	Range Agreed	1	4	Date Agreed	31/05/2019	4	24/04/2018	4	Recruitment Finished
16	17/SC/0122	224090	AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)	Range Agreed	4	8	Date Agreed	28/02/2018	8	28/02/2018	8	Recruitment Finished
17	17/LO/0794	223700	A 52-Week Multicenter, Randoimized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Number Agreed	2	2	Date Agreed	13/05/2019	1	18/05/2018	1	Recruitment Finished
18	16/LO/1211	207428	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics,Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera? in Anti TNFInadequate Responder Patients with Moderate to Seve	Range Agreed	1	2	Date Agreed	01/08/2018	0	20/07/2018	0	Recruitment Finished
19	18/NW/0412	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula for children over 1 year of age	Range Agreed	1	7	Date Agreed	31/08/2018	5	31/08/2018	5	Recruitment Finished
20	13/NW/0003	117310	AKPA 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Severe Sepsis and Coagulopathy	Range Agreed	1	6	Date Agreed	30/09/2018	3	13/09/2018	3	Recruitment Finished

21	13/NI/0123	135437	MILES - UK: Post marketing, multicenter, single arm, obervational clinical registry to evaluate safety and efficacy of BioMime sirolimus eluting stent system in all comers real world population with coronary artery stenosis in United Kingdom	Number Agreed	10	10	Date Agreed	31/07/2018	25	31/08/2018	25	Recruitment Finished
22	15/LO/1079	177212	A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem? Therapy in Subjects with Acute RespiratoryDistress Syndrome	Range Agreed	2	3	Date Agreed	31/03/2018	2	19/09/2018	4	Recruitment Finished
23	17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studyto Evaluate the Safety and Efficacy of CCX168 (Avacopan) inPatients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab orCyclophosph	Number Agreed	2	2	Date Agreed	31/12/2018	2	04/07/2018	2	Recruitment Finished
24	17/EM/0405	223871	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Range Agreed	1	10	Date Agreed	30/09/2018	3	21/09/2018	3	Recruitment Finished
25	16/NW/0089	165834	IronWood	Number Agreed	40	40	Date Agreed	30/04/2017	18	01/08/2018	42	Recruitment Finished
26	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study toEvaluate the Safety and Efficacy of VX-659 CombinationTherapy in Subjects Aged 18 Years and Older With CysticFibrosis	Number Agreed	4	4	Date Agreed	28/02/2018	1	02/04/2018	1	Recruitment Finished
27	18/NE/0103	241640	A Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous for the F508del Mutation (F/F)	Range Agreed	1	2	Date Agreed	31/01/2018	0	21/07/2018	2	Recruitment Finished
28	17/NW/0635	228844	A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough	Number Agreed	10	10	Date Agreed	08/10/2018	0	28/09/2018	0	Withdrawn By Sponsor
29	18/NE/0104	241180	A phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapyin subjects with cystic fibrosis who are heterozygous for the F508del mutation and a minimal function mutation (F/MF)	Number Agreed	2	2	Date Agreed	31/08/2018	0	21/07/2018	3	Recruitment Finished
30	18/LO/0068	235852	Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)	Number Agreed	1	1	Date Agreed	31/10/2019	0	10/10/2018	0	Withdrawn By Sponsor

31	18/NE/0200	244356	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Range Agreed	1	3	Date Agreed	31/10/2018	3	31/10/2018	3	Recruitment Finished
32	15/NW/0769	171345	CTP005 - A Feasibility study of the Use of ReCell? Autologous Cell Harvesting Device for Diabetic Foot Ulcers	Range Agreed	6	21	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished
33	15/LO/2045	193136	A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)	Range Agreed	1	2	Date Agreed	01/05/2018	2	27/06/2018	2	Recruitment Finished
34	15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	2	2	Date Agreed	31/10/2018	2	08/10/2018	2	Recruitment Finished
35	17/NE/0115	218417	MULTICENTER, INTERNATIONAL, DOUBLE-BLIND, TWO-ARM, RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD	Number Agreed	2	2	Date Agreed	30/04/2018	0	30/04/2018	0	Recruitment Finished
36	17/EE/0255	227279	VOLCANO 2	Number Agreed	10	10	Date Agreed	23/02/2018	0	11/04/2018	5	Recruitment Finished
37	17/YH/0313	232939	RelAxCough	Range Agreed	10	15	Date Agreed	30/11/2018	12	29/12/2018	12	Recruitment Finished
38	17/EM/0060	215678	Protocol I1F-MC-RHBY. A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in P	Number Agreed	2	2	Date Agreed	28/09/2018	2	28/09/2018	2	Recruitment Finished
39	17/EM/0324	225749	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotidecapsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatinreceptor ligands (SRL	Range Agreed	1	2	Date Agreed	31/08/2018	2	01/10/2018	2	Recruitment Finished
40	18/SC/0098	241440	A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens	Number Agreed	2	2	Date Agreed	28/02/2019	2	30/08/2018	2	Recruitment Finished